Skip to content

What a GLP-1 costs under Medicare Part D in 2026

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Medicare Part D GLP-1 cost in 2026 follows the standard benefit if your plan covers the drug: a deductible of no more than $615, then 25% coinsurance until your out-of-pocket spending on covered Part D drugs reaches $2,100, then nothing for the rest of the year, per Medicare.gov. The $50 Medicare GLP-1 Bridge copay is separate and doesn't count toward the deductible or the cap.

Source: Medicare GLP-1 Bridge

Key takeaways

  • If your Part D plan covers your GLP-1, your 2026 deductible can't be more than $615.
  • After that you pay 25% until your out-of-pocket spending on covered Part D drugs reaches $2,100.
  • The $50 Bridge copay doesn't count toward your Part D deductible or cap.
  • You can't pick the cheaper system. The reason for the prescription and your diagnoses decide it.
  • Extra Help and the Medicare Prescription Payment Plan don't apply to the Bridge copay.

A GLP-1 can reach you through two different payment systems in 2026 if you’re on Medicare, and they have nothing in common. One is the ordinary Part D benefit, with its deductible, coinsurance and annual cap. The other is the Medicare GLP-1 Bridge, with a flat copay that touches none of those. Once you know which one your prescription falls under, you know what the year will cost. This page is part of our Medicare and GLP-1 guide.

First: which system is your prescription in?

Part D applies when the GLP-1 is prescribed for a use Part D can cover. CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH with moderate to advanced liver scarring as eligible indications. It also names reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.

The Bridge applies when Wegovy, Foundayo or the Zepbound KwikPen is prescribed for weight management to someone who meets the Bridge criteria. Part D doesn’t cover drugs used for weight loss.

You can’t pick the cheaper system. The reason for the prescription and your diagnoses decide it. The Bridge explainer sets out the criteria.

Part D in 2026: four things to know

These apply to drugs your Part D plan covers.

Deductible: no more than $615

The deductible is what you pay before your plan starts sharing the cost. No Medicare drug plan may have a deductible of more than $615 in 2026 ($700 in 2027). Some plans have no deductible. If yours has one, your first fills of the year cost more than later ones, so ask your plan what a fill will cost before you meet the deductible.

Coinsurance: 25%

After the deductible, you pay 25% of the cost as coinsurance for your generic and brand-name drugs, until your out-of-pocket spending on covered Part D drugs reaches the cap. Plans set their own tiers and cost sharing within Medicare’s rules, so ask your plan what its figure is for your drug.

Out-of-pocket cap: $2,100

Once your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027), you move into catastrophic coverage automatically. You won’t have to pay out of pocket for covered Part D drugs for the rest of the calendar year. The total counts certain payments made on your behalf, such as through the Extra Help program.

If you’re taking a brand-name GLP-1 through Part D all year, the cap is the number that matters most. It’s the ceiling on what all your covered Part D drugs together can cost you in the year, and it resets each January.

Here’s how the three numbers work together. Say your plan has the highest deductible allowed, $615, and uses 25% coinsurance. You pay that deductible first. Then you pay 25% of each fill. When your out-of-pocket total reaches $2,100, you stop paying for covered Part D drugs until the next calendar year.

Medicare Prescription Payment Plan

The cap limits the total, but early-year costs can still come in a lump. The Medicare Prescription Payment Plan is a payment option that spreads your out-of-pocket costs for plan-covered drugs across the calendar year. All plans offer it. Joining is voluntary and there’s no cost to take part. Medicare is direct about its limit: it might help you manage your monthly expenses, but it doesn’t save you money or lower your drug costs. Ask your plan how to join.

Extra Help

Extra Help is a Medicare program that helps people with limited income and resources pay Part D premiums, deductibles, coinsurance and other costs. The 2026 limits are $23,940 in income and $18,090 in resources for an individual, and $32,460 and $36,100 for a married couple.

Medicare.gov gives the 2027 amounts for what people with Extra Help pay: a $0 plan premium, a $0 plan deductible, and up to $14.40 for each brand-name drug filled at one of the plan’s participating pharmacies.

The Bridge copay sits outside all of this

The Medicare GLP-1 Bridge charges $50 for a one-month supply. CMS says Bridge drugs are provided outside the Part D benefit payment flow and coverage. In plain terms:

  • No deductible. The Part D deductible doesn’t apply. You pay the copay from the first fill.
  • No credit toward the cap. No part of the copay counts toward your true out-of-pocket costs. It doesn’t move you toward catastrophic coverage.
  • No Extra Help. There’s no low-income subsidy for Bridge fills. If you have Extra Help, you still pay the full Bridge copay.
  • No payment plan. You can’t spread the copay out with the Medicare Prescription Payment Plan.
  • No coupons. Coupons and discount programs may not be applied to Bridge claims.

Behind the copay, participating manufacturers supply the drugs at a net price of $245 per monthly supply. None of that counts toward your Part D gross covered drug costs either.

So a year on the Bridge is simple to work out: the copay, times the number of monthly fills. Weekly pens come as 28-day supplies and tablets as 30-day supplies. That makes a full calendar year 13 fills of the Wegovy pen or Zepbound KwikPen, or 12 fills of the Wegovy pill or Foundayo. The Bridge only allows one monthly supply per fill.

Part D or Bridge: which costs less over a year?

It depends on what else you take, and you don’t get to choose the route. But the comparison is worth understanding.

Under the Bridge, your GLP-1 spending is predictable and separate. It adds to whatever your other drugs cost under Part D.

Under Part D, a covered GLP-1 counts toward the $2,100 cap along with everything else. If your other medicines already take you to the cap, a GLP-1 covered by your plan adds little or nothing beyond it. If the GLP-1 is your only expensive drug, the cap limits your yearly cost, but that cost could be well above a year of Bridge copays, depending on your plan’s deductible and cost sharing.

That’s why a Part D covered diagnosis isn’t automatically the cheaper path, and why your plan’s details matter. Ask your plan for the drug’s tier and your cost per fill before and after the deductible.

2027: the negotiated semaglutide price

Semaglutide is among the 15 drugs with a negotiated Medicare price, which the statute calls a maximum fair price, taking effect on January 1, 2027. CMS and Novo Nordisk agreed $274 for a 30-day supply, which CMS compares with a 2024 list price of $959, a 71% discount.

CMS gives per-package figures for three commonly used forms:

  • one Ozempic 4 mg/3 mL pen: $276.78
  • 30 Rybelsus 7 mg tablets: $276.78
  • four Wegovy 2.4 mg pens: $385.63

By law, Part D plans, including Medicare Advantage drug plans, must include the selected drugs on their formularies (their lists of covered drugs).

Read these carefully. They’re negotiated prices for the drug under Part D. The fact sheet doesn’t state what a beneficiary’s copay will be, and your share still follows your plan’s benefit. And they apply to Part D covered uses: the Wegovy figure doesn’t by itself make Wegovy covered for weight loss. For weight management, the Bridge and its copay continue through December 31, 2027.

Other 2027 changes: the deductible limit rises to $700 and the out-of-pocket cap to $2,400.

If you end up paying cash

Money you spend outside Medicare doesn’t count toward any Part D limit. The manufacturers’ self-pay programs are cash programs in which no insurance is used, and their terms say you can’t seek reimbursement. Our cost calculator prices a year on any route, and the GLP-1 cost guide explains the cash options.

Questions to take to your plan

  1. Is this GLP-1 on the formulary for my diagnosis, and on which tier?
  2. Does it need prior authorization (the plan’s approval before it pays) or a formulary exception?
  3. What is my deductible, and what will I pay per fill before and after it?
  4. How close am I to the out-of-pocket cap this year?
  5. How do I join the Medicare Prescription Payment Plan?

For plan-type questions, Medicare’s number is 1-800-MEDICARE (1-800-633-4227). For drug-specific routes, see Wegovy and Zepbound.

Frequently asked questions

What is the Medicare Part D out-of-pocket maximum in 2026?

Out-of-pocket spending on covered Part D drugs is capped at $2,100 in 2026, rising to $2,400 in 2027. The total includes certain payments made on your behalf, such as through Extra Help. Once you reach it, you get catastrophic coverage automatically and pay nothing out of pocket for covered Part D drugs for the rest of the calendar year.

Does the $50 Bridge copay count toward the $2,100 cap?

No. CMS says Bridge drugs are provided outside the Part D benefit payment flow and coverage. So the Part D deductible doesn't apply, and no part of the $50 copay counts toward your true out-of-pocket costs. Twelve or thirteen Bridge copays in a year bring you no closer to catastrophic coverage for your other drugs.

Can I spread GLP-1 costs over the year with the Medicare Prescription Payment Plan?

For a GLP-1 covered by your Part D plan, yes. The payment plan spreads out-of-pocket costs for plan-covered drugs across the calendar year. All plans offer it, joining is voluntary and costs nothing, and it doesn't lower your costs. You can't use it for the Bridge copay, because Bridge fills aren't Part D covered drugs.

What is the Medicare negotiated price for Ozempic and Wegovy?

For 2027, CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide (Ozempic, Rybelsus, Wegovy), a 71% discount from the 2024 list price of $959. Per package, CMS lists $276.78 for one Ozempic 4 mg/3 mL pen and $385.63 for four Wegovy 2.4 mg pens. The prices take effect January 1, 2027.

Does Extra Help lower the cost of a GLP-1?

For a GLP-1 covered by your Part D plan, Extra Help helps pay premiums, deductibles and coinsurance if your income and resources are within its limits: $23,940 and $18,090 for an individual in 2026. It doesn't lower the Bridge copay. CMS says there's no low-income subsidy for Bridge fills.

Sources (14)

  1. 1.
    Medicare.gov: How much does Medicare drug coverage cost?
    “After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
  2. 2.
    Medicare.gov: How much does Medicare drug coverage cost?
    “No Medicare drug plan may have a deductible more than $615 in 2026 ($700 in 2027). Some Medicare drug plans don’t have a deductible.”
  3. 3.
    Medicare.gov: What’s the Medicare Prescription Payment Plan?
    “The Medicare Prescription Payment Plan is a payment option that works with your current drug coverage to help you manage your out-of-pocket costs for drugs covered by your plan by spreading them across the calendar year (January–December). [...] All plans offer this payment option, and participation is voluntary. [...] There’s no cost to participate in the Medicare Prescription Payment Plan. [...] This payment option might help you manage your monthly expenses, but it doesn’t save you money or lower your drug costs.”
  4. 4.
    Medicare.gov: Help with drug costs
    “"Extra Help" is a Medicare program to help people with limited income and resources pay Medicare drug coverage (Part D) premiums, deductibles, coinsurance, and other costs. [...] Income and resource limits in 2026: [table] Individual: Income limit $23,940, Resource limit $18,090. Married couple: Income limit $32,460, Resource limit $36,100.”
  5. 5.
    Medicare.gov: Help with drug costs
    “What you'll pay under Extra Help in 2027 Plan premium: $0 Plan deductible: $0 Prescriptions you fill at one of your plan's participating pharmacies: Up to $5.80 for each generic drug Up to $14.40 for each brand-name drug”
  6. 6.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  7. 7.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4130-13. Description of package: 4mg/3mL Pen, 1 Pen (Ozempic). MFP per package: $276.78.”
  8. 8.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4307-30. Description of package: 7mg, 30 Tablets (Rybelsus). MFP per package: $276.78.”
  9. 9.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4524-14. Description of package: 2.4mg/0.75mL Pen, 4 Pens (Wegovy). MFP per package: $385.63.”
  10. 10.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “These negotiated prices will become effective on January 1, 2027. [...] As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
  11. 11.
    CMS: Information for Part D Plans
    “Under the Medicare GLP-1 Bridge, participating manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply. Coverage of eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge is provided outside of the Part D benefit payment flow and coverage. As such, no part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC), and no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.”
  12. 12.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  13. 13.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  14. 14.